The hardest problems in gene therapy for neurological disease sit at the intersection of science, medicine, regulation, manufacturing, financing, and patient access — and they can only be solved by people from all of those worlds thinking together, not in parallel.

Gene4Neuro is built around that conviction.

We convene the complete value chain of this field — not to present at each other, but to work together. The format is deliberately intimate and deliberately demanding. Every session expects participation. Every participant is selected because their perspective is genuinely needed in the room. The result is something that no larger conference and no bilateral meeting can replicate: two days of sustained, high-level, cross-disciplinary dialogue between the people who are actually moving this field forward.

For early and growth-stage companies, Gene4Neuro offers something specific and rare: direct, sustained engagement with investors who understand your science, pharma decision-makers who are actively looking for what you are building, and scientific and clinical leaders whose endorsement and collaboration can define your trajectory.

For researchers and clinicians, it offers honest conversation with the people translating discovery into development — and the opportunity to shape the scientific agenda of the companies and funds most active in your area.

For investors and industry, it offers curated access to the most promising science and the most capable teams in the field, in a setting where genuine assessment is possible.

For patient organizations and foundations, it offers a seat at the table where the decisions that affect your communities are being made — and the influence that comes from being present when those decisions take shape.

Everyone in the room needs everyone else in the room. That is not an aspiration. It is the design principle.

For three decades, gene therapy has promised to treat disease at its source — to correct the genetic errors that cause some of the most devastating neurological conditions known to medicine. For most of that time, the promise outpaced the reality.  That has changed.

Approved gene therapies are now reaching children with SMA, Batten disease, AADC deficiency, and adrenoleukodystrophy. Patient communities that once had no therapeutic options are receiving treatments that work. The regulatory frameworks that govern these therapies — at the EMA, the FDA, and beyond — have been shaped by hard-won experience and are more navigable than at any point in the field's history. The manufacturing challenges that once made commercial-scale gene therapy seem impossibly distant are being solved, one process innovation at a time.

And the frontier is expanding into territory that affects millions rather than thousands.

Huntington's disease. ALS. GBA-associated Parkinson's disease. Frontotemporal Dementia. Genetic epilepsies. The same scientific toolkit — refined AAV vectors with improved CNS tropism, antisense approaches,  RNAi — that proved itself in rare pediatric diseases is now being directed at the neurodegenerative diseases of aging. The clinical programs are multiplying. The investment is starting to follow in spite of the geopolitical situation. Pharma organizations that watched from a distance are now actively seeking partnerships, licensing opportunities, and acquisitions.

The question is no longer whether gene therapy will transform neurological medicine. It will. The question being answered right now — in laboratories, in clinical trials, in boardrooms, and in the conversations between the people who fund and build and regulate and prescribe these therapies — is how fast, for which diseases first, what are the remaining barriers to get there, and who will solve these.

Those are exactly the questions Gene4Neuro is designed to address. In June 2026, in Pamplona, the researchers generating the answers, the entrepreneurs and executives building the companies, the investors providing the capital, and the clinicians and parents and patient advocates who understand what is truly at stake will spend two days working on them together.

If those questions are central to your work, you should be in that room.